Last update Sept. 15, 2022
Limited compatibility
Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.
Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.
Thank you for helping to protect and promote breastfeeding.
Pholcodine belongs to this group or family:
Main tradenames from several countries containing Pholcodine in its composition:
| Variable | Value | Unit |
|---|---|---|
| Oral Bioavail. | 88 | % |
| Molecular weight | 416 | daltons |
| Protein Binding | 21 - 23 | % |
| VD | 3.8 | l/Kg |
| pKa | 13.78 | - |
| Tmax | 1.3 | hours |
| T½ | 45 | hours |
Write us at elactancia.org@gmail.com
e-lactancia is a resource recommended by Academy of Breastfeeding Medicine - 2012 of United States of America
Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM
Pholcodine is a centrally acting opioid antitussive that has actions and uses similar to those of dextromethorphan. It has a mild sedative effect and no analgesic effect. May cause respiratory depression and hypotension like codeine. Does not cause addiction (Blanchard 2013). It is administered orally three or four times a day.
Since the last update we have not found published data on its excretion in breastmilk.
Its pharmacokinetic data do not allow a good prediction of the possible excretion in breast milk, because while its low binding to plasma proteins and long half-life would facilitate it, its very large volume of distribution would make it difficult.
The administration of pholcodine causes the production of anti-curare antibodies that persist for several years, with the risk of severe anaphylaxis during anesthesia. (Florvaag 2012, Guttormsen 2010, Harboe 2007)
Until more published data is known about this drug in relation to breastfeeding, known safer alternatives are preferable, especially during the neonatal period and in the event of prematurity.